Protagonist Therapeutics announced positive results from the Phase 3 ICONIC-LEAD study for icotrokinra in adolescents with moderate-to-severe plaque psoriasis. The data showed that 75% of adolescents treated with icotrokinra achieved completely clear skin (IGA 0).
Furthermore, 84% of adolescents achieved clear or almost clear skin (IGA 0/1) at Week 16, demonstrating significant efficacy in this patient population. The study also reported a favorable safety profile for the once-daily oral pill.
ICONIC-LEAD is noted as the first Phase 3 registrational study in moderate-to-severe plaque psoriasis to include a significant adolescent cohort. These results support icotrokinra's potential as a comprehensive treatment option across different age groups.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.